Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
More information 👇
🆔 @partohair
More information 👇
🆔 @partohair
Results indicate the brain receives less dose with radiosurgery, even when treating 10 or more lesions
January 3, 2018 — Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits in the brain, but the best technique to deliver radiation can be controversial. Whole-brain radiation therapy, as its name suggest, treats the entire brain but can be associated with notable cognitive side effects. Another strategy, radiosurgery, directs highly-focused radiation only to the sites of metastasis, largely sparing the normal brain.
Whole-brain radiation delivers a radiation dose of approximately 30 Gy to the entire brain. A technique known as “hippocampal-sparing” or “hippocampal-avoidance” radiation delivers the same dose of radiation to the bulk of the brain, but only about 10 Gy to the hippocampus. The maximum radiation dose experienced with radiosurgery, even with many metastases, was 1.2 Gy in the hippocampus and 0.8 Gy across the whole brain.
“The very low doses of radiation to the normal brain observed with radiosurgery compared to whole-brain radiation has the potential to dramatically alter the risk of cognitive side effects,” said Rusthoven. “As the field of oncology evolves, we have to evolve with it. Patients with cancer who are eligible for targeted therapies are living longer than ever before, making treatment strategies that support long term quality of life even more important.”
For more information :
https://www.itnonline.com/content/study-compares-radiosurgery-and-whole-brain-radiation-lung-cancer-patients-multiple-brain
🆔 @partohair
January 3, 2018 — Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits in the brain, but the best technique to deliver radiation can be controversial. Whole-brain radiation therapy, as its name suggest, treats the entire brain but can be associated with notable cognitive side effects. Another strategy, radiosurgery, directs highly-focused radiation only to the sites of metastasis, largely sparing the normal brain.
Whole-brain radiation delivers a radiation dose of approximately 30 Gy to the entire brain. A technique known as “hippocampal-sparing” or “hippocampal-avoidance” radiation delivers the same dose of radiation to the bulk of the brain, but only about 10 Gy to the hippocampus. The maximum radiation dose experienced with radiosurgery, even with many metastases, was 1.2 Gy in the hippocampus and 0.8 Gy across the whole brain.
“The very low doses of radiation to the normal brain observed with radiosurgery compared to whole-brain radiation has the potential to dramatically alter the risk of cognitive side effects,” said Rusthoven. “As the field of oncology evolves, we have to evolve with it. Patients with cancer who are eligible for targeted therapies are living longer than ever before, making treatment strategies that support long term quality of life even more important.”
For more information :
https://www.itnonline.com/content/study-compares-radiosurgery-and-whole-brain-radiation-lung-cancer-patients-multiple-brain
🆔 @partohair
Imaging Technology News
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits in the brain, but the best technique…
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
More information 👇
🆔 @partohair
More information 👇
🆔 @partohair
Prominent cancer centers expand portfolio of patient-centric treatment solutions with Xoft’s painless, scar-free solution
January 2, 2018 — iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients with non-melanoma skin cancer (NMSC), including individuals precluded from surgery or those seeking a non-invasive option, will now have access to a proven alternative.
The Xoft technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation therapy directly to the lesion, reducing the risk of damage to surrounding healthy tissue. The mobile system can be easily maneuvered from room to room, while minimal shielding requirements enable clinicians to deliver treatment in a standard exam room, offering a highly-efficient, flexible solution.
The Xoft System is cleared by the U.S. Food and Drug Administration (FDA), CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer and gynecological cancers.
For more information :
https://www.itnonline.com/content/california-us-oncology-network-centers-adopt-xoft-electronic-brachytherapy-system-early
🆔 @partohair
January 2, 2018 — iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients with non-melanoma skin cancer (NMSC), including individuals precluded from surgery or those seeking a non-invasive option, will now have access to a proven alternative.
The Xoft technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation therapy directly to the lesion, reducing the risk of damage to surrounding healthy tissue. The mobile system can be easily maneuvered from room to room, while minimal shielding requirements enable clinicians to deliver treatment in a standard exam room, offering a highly-efficient, flexible solution.
The Xoft System is cleared by the U.S. Food and Drug Administration (FDA), CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer and gynecological cancers.
For more information :
https://www.itnonline.com/content/california-us-oncology-network-centers-adopt-xoft-electronic-brachytherapy-system-early
🆔 @partohair
Imaging Technology News
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based centers from The US Oncology Network – Santa Clarita Radiation Therapy Center and Sherman Oaks Radiation Therapy Center. Local patients…
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
More information 👇
🆔 @partohair
More information 👇
🆔 @partohair
Water phantom system enables fast and seamless beam scanning
January 2, 2018 — IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian Halcyon radiation therapy system in Europe to go clinical, at the hospital UZ Leuven in Belgium, using IBA Dosimetry’s Blue Phantom water phantom system.
The Blue Phantom system enables fast and seamless beam scanning workflows that are ideal for verification and annual quality assurance (QA) of the Varian Halcyon. Next to the compact design, the phantom’s conveniently accessible micro-leveling frame enables fast and precise system setup.
For more information :
https://www.itnonline.com/content/blue-phantom-system-used-acceptance-first-european-varian-halcyon-machine
🆔 @partohair
January 2, 2018 — IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian Halcyon radiation therapy system in Europe to go clinical, at the hospital UZ Leuven in Belgium, using IBA Dosimetry’s Blue Phantom water phantom system.
The Blue Phantom system enables fast and seamless beam scanning workflows that are ideal for verification and annual quality assurance (QA) of the Varian Halcyon. Next to the compact design, the phantom’s conveniently accessible micro-leveling frame enables fast and precise system setup.
For more information :
https://www.itnonline.com/content/blue-phantom-system-used-acceptance-first-european-varian-halcyon-machine
🆔 @partohair
Imaging Technology News
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian Halcyon machine in Europe to go clinical, at the hospital UZ Leuven in Belgium, using IBA Dosimetry’s Blue Phantom water phantom system.
👆👆از دوستانی که علاقه به همکاری در حوزه ی شبیه سازی نسل جدید سلول های خورشیدی هستند در خواست می شود تا علاقمندی و رزومه خود را به ای دی اینجانب ارسال نمایند.
این پروژه در همکاری با محققین دانشگاه UCL انگلستان انجام خواهد شد.
این پروژه در همکاری با محققین دانشگاه UCL انگلستان انجام خواهد شد.
🌐بيشتر آدمها فكر ميكنن موفقيت و شكست دو جاده ى از هم جدا هستن. در صورتيكه هر شكستى ، جاى پا رو براى قدم هاتون تا رسيدن به موفقيت درست ميكنه
ID:@partohair
ID:@partohair
⬛️ ⬛️
نه نوحی هست
تا از موج و طوفان بَر کشد ما را...
نه موسایی
که بشکافد عصایش آبِ دریا را...
نه ابراهیم
تا ناگه گلستان سازد از آتش...
هموطن تسلیت....
🆔: @partohair
نه نوحی هست
تا از موج و طوفان بَر کشد ما را...
نه موسایی
که بشکافد عصایش آبِ دریا را...
نه ابراهیم
تا ناگه گلستان سازد از آتش...
هموطن تسلیت....
🆔: @partohair
با سلام
شرکتی که نماینده کمپانی Brainlab می باشد، (حوزه رادیوتراپی و طراحی درمان)،جهت تکمیل منابع انسانی خود در حوزه فروش از واجدین شرایط زیر دعوت به همکاری می نماید.
۱-مدرک پرتو پزشکی و یا سایر موارد مرتبط.
۲- حداکثر سن ۳۰ سال
۳-تمایل به همکاری بلند مدت
۴- ساکن تهران
لذا از علاقه مندان واجد شرایط دعوت میگردد تا رزومه خود را به آدرس الکترونیکی ذیل ارسال فرمایند
cv@atcgroup.ir
🆔 @partohair
شرکتی که نماینده کمپانی Brainlab می باشد، (حوزه رادیوتراپی و طراحی درمان)،جهت تکمیل منابع انسانی خود در حوزه فروش از واجدین شرایط زیر دعوت به همکاری می نماید.
۱-مدرک پرتو پزشکی و یا سایر موارد مرتبط.
۲- حداکثر سن ۳۰ سال
۳-تمایل به همکاری بلند مدت
۴- ساکن تهران
لذا از علاقه مندان واجد شرایط دعوت میگردد تا رزومه خود را به آدرس الکترونیکی ذیل ارسال فرمایند
cv@atcgroup.ir
🆔 @partohair
This media is not supported in your browser
VIEW IN TELEGRAM
این انیمیشن زیبا به صورت کامل در مورد انفجار پرتوهای گاما و اثرات آن بر زمین و دیگر نقاط جهان توضیح میدهد.
🆔: @partohair
🆔: @partohair
میان پرواز تا پرتاب "تفـاوت" از زمین تا
آسمان است! وقتیکه پرواز کنی
آنجا میرسی که خودت میخواهی و
پرتابت که کنند آنجا میروی که "آنها"میخواهند پس پرواز را بیاموز.
ID: @partohair
آسمان است! وقتیکه پرواز کنی
آنجا میرسی که خودت میخواهی و
پرتابت که کنند آنجا میروی که "آنها"میخواهند پس پرواز را بیاموز.
ID: @partohair
هر شب شما و تخت خوابتان 858,240 کیلومتر به دور خورشید و 6,256,000 کیلومتر به دور مرکز کهکشان راه شیری سفر ميكنيد !
🆔: @partohair
🆔: @partohair
Forwarded from Shabnam Taleei